{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T15:45:21Z","timestamp":1770738321650,"version":"3.49.0"},"reference-count":54,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2002,10,1]]},"abstract":"<jats:p> PURPOSE: To determine the efficacy, feasibility, and toxicity of a new regimen for locally advanced oropharyngeal carcinoma. <\/jats:p><jats:p> PATIENTS AND METHODS: Patients had technically resectable stage III\/IV squamous cell carcinoma of the oropharynx, exclusive of T1-2N1. Induction chemotherapy consisted of carboplatin (area under the curve formula equal to 6) and paclitaxel 200 mg\/m<jats:sup>2<\/jats:sup> for two cycles, followed by re-evaluation. Patients with major response continued to definitive radiotherapy (70 Gy over 7 weeks) plus concurrent once-weekly paclitaxel (30 mg\/m<jats:sup>2<\/jats:sup>\/wk). Patients with advanced neck disease also underwent post\u2013radiation therapy neck dissection and two more chemotherapy cycles. <\/jats:p><jats:p> RESULTS: Fifty-three patients were enrolled. Median follow-up was 31 months (minimum follow-up for survivors was 18 months). The major response rate to induction chemotherapy was 89%; 90% of patients had a complete response after concurrent chemoradiation. Actuarial survival at 3 years was 70%, and 3-year event-free survival was 59%. The 3-year actuarial locoregional control was 82% and the 3-year actuarial rate of distant metastases was 19%. Organ preservation was achieved in 77% of all patients. One patient (2%) died during therapy. Late grade 3 toxicity occurred in 24% of patients, consisting mainly of chronic dysphagia\/aspiration and\/or radiation soft tissue ulceration. The treatment-related mortality rate was 4% (two patients died from respiratory failure). <\/jats:p><jats:p> CONCLUSION: Response to induction chemotherapy as studied in this trial was not useful as a predictive marker for ultimate outcome or organ conservation. Overall, however, this regimen offers good disease control and survival for patients with locally advanced oropharyngeal carcinoma, comparable with other concurrent chemoradiation programs. Further study of similar protocols is indicated. <\/jats:p>","DOI":"10.1200\/jco.2002.11.026","type":"journal-article","created":{"date-parts":[[2002,9,26]],"date-time":"2002-09-26T18:22:56Z","timestamp":1033064576000},"page":"3964-3971","source":"Crossref","is-referenced-by-count":177,"title":["Organ Preservation Therapy Using Induction Plus Concurrent Chemoradiation for Advanced Resectable Oropharyngeal Carcinoma: A University of Pennsylvania Phase II Trial"],"prefix":"10.1200","volume":"20","author":[{"given":"Mitchell","family":"Machtay","sequence":"first","affiliation":[{"name":"From the Department of Radiation Oncology, Division of Medical Oncology, Department of Medicine, and Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania Medical Center, Philadelphia, and Pocono Medical Center, East Stroudsburg, PA; and Department of Medical Oncology, Falmouth Hospital Oncology Center, Mashpee, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David I.","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Division of Medical Oncology, Department of Medicine, and Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania Medical Center, Philadelphia, and Pocono Medical Center, East Stroudsburg, PA; and Department of Medical Oncology, Falmouth Hospital Oncology Center, Mashpee, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Hershock","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Division of Medical Oncology, Department of Medicine, and Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania Medical Center, Philadelphia, and Pocono Medical Center, East Stroudsburg, PA; and Department of Medical Oncology, Falmouth Hospital Oncology Center, Mashpee, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Jones","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Division of Medical Oncology, Department of Medicine, and Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania Medical Center, Philadelphia, and Pocono Medical Center, East Stroudsburg, PA; and Department of Medical Oncology, Falmouth Hospital Oncology Center, Mashpee, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirnett","family":"Williamson","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Division of Medical Oncology, Department of Medicine, and Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania Medical Center, Philadelphia, and Pocono Medical Center, East Stroudsburg, PA; and Department of Medical Oncology, Falmouth Hospital Oncology Center, Mashpee, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Greenberg","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Division of Medical Oncology, Department of Medicine, and Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania Medical Center, Philadelphia, and Pocono Medical Center, East Stroudsburg, PA; and Department of Medical Oncology, Falmouth Hospital Oncology Center, Mashpee, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory S.","family":"Weinstein","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Division of Medical Oncology, Department of Medicine, and Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania Medical Center, Philadelphia, and Pocono Medical Center, East Stroudsburg, PA; and Department of Medical Oncology, Falmouth Hospital Oncology Center, Mashpee, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor M.","family":"Aviles","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Division of Medical Oncology, Department of Medicine, and Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania Medical Center, Philadelphia, and Pocono Medical Center, East Stroudsburg, PA; and Department of Medical Oncology, Falmouth Hospital Oncology Center, Mashpee, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ara A.","family":"Chalian","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Division of Medical Oncology, Department of Medicine, and Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania Medical Center, Philadelphia, and Pocono Medical Center, East Stroudsburg, PA; and Department of Medical Oncology, Falmouth Hospital Oncology Center, Mashpee, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randal S.","family":"Weber","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, Division of Medical Oncology, Department of Medicine, and Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania Medical Center, Philadelphia, and Pocono Medical Center, East Stroudsburg, PA; and Department of Medical Oncology, Falmouth Hospital Oncology Center, Mashpee, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-114483","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(95)02028-4"},{"key":"R2-114483","doi-asserted-by":"crossref","unstructured":"Sessions  DG:   Surgical resection and reconstruction for cancer of the base of tongue.  Otalaryngol Clin North Am 16:  309,1983-322,","DOI":"10.1016\/S0030-6665(20)32064-8"},{"key":"R3-114483","doi-asserted-by":"publisher","DOI":"10.1002\/hed.2880130404"},{"key":"R4-114483","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0347(199709)19:6<494::AID-HED6>3.0.CO;2-U"},{"key":"R5-114483","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(83)90059-7"},{"key":"R6-114483","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19921115)70:10<2388::AID-CNCR2820701003>3.0.CO;2-M"},{"key":"R7-114483","doi-asserted-by":"publisher","DOI":"10.1002\/hed.2890100105"},{"key":"R8-114483","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9610(05)80338-1"},{"key":"R9-114483","doi-asserted-by":"publisher","DOI":"10.1053\/ajot.2001.26492"},{"key":"R11-114483","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200010000-00016"},{"key":"R12-114483","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R14-114483","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900801)66:3<564::AID-CNCR2820660326>3.0.CO;2-D"},{"key":"R15-114483","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2715"},{"key":"R16-114483","unstructured":"Mantz  CA,   Vokes  EE,   Stenson  K,  et al:   Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer.  Cancer J 7:  140,2001-148,"},{"key":"R17-114483","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000901)89:5<939::AID-CNCR1>3.0.CO;2-6"},{"key":"R18-114483","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.4.876"},{"key":"R19-114483","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/84.11.877"},{"key":"R20-114483","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0347(199710)19:7<567::AID-HED2>3.0.CO;2-5"},{"key":"R21-114483","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.2.385"},{"key":"R22-114483","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1318"},{"key":"R23-114483","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(97)00092-8"},{"key":"R24-114483","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0347(199809)20:6<497::AID-HED2>3.0.CO;2-H"},{"key":"R25-114483","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1405"},{"key":"R26-114483","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.13.890"},{"key":"R27-114483","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.671"},{"key":"R28-114483","doi-asserted-by":"publisher","DOI":"10.1002\/hed.2880120306"},{"key":"R29-114483","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.24.2081"},{"key":"R30-114483","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1512"},{"key":"R31-114483","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)90011-4"},{"key":"R32-114483","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058905"},{"key":"R33-114483","unstructured":"Forastiere  AA,   Berkey  B,   Maor  M,  et al:   Phase III trial to preserve the larynx:  Induction chemotherapy and radiotherapy versus concomitant chemoradiotherapy versus radiotherapy alone, intergroup trial R91-11.   Proc Am Soc Clin Oncol 20:  2a,2001  (abstr 4)"},{"key":"R34-114483","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0347(199709)19:6<500::AID-HED7>3.0.CO;2-2"},{"key":"R35-114483","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-2391(96)90535-2"},{"key":"R36-114483","doi-asserted-by":"publisher","DOI":"10.1288\/00005537-199410000-00003"},{"key":"R37-114483","doi-asserted-by":"publisher","DOI":"10.1002\/hed.2890060305"},{"key":"R38-114483","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9610(97)81724-2"},{"key":"R39-114483","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.7.1961"},{"key":"R40-114483","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.125.2.142"},{"key":"R41-114483","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870801)60:3<301::AID-CNCR2820600306>3.0.CO;2-V"},{"key":"R42-114483","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(92)90642-U"},{"key":"R43-114483","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1310"},{"key":"R44-114483","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)90172-4"},{"key":"R45-114483","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(00)00663-5"},{"key":"R46-114483","doi-asserted-by":"crossref","unstructured":"Bourhis  J,   Lapeyre  M,   Tortochaux  J,  et al:   Very accelerated versus conventional radiotherapy in HNSCC:  Results of the GORTEC 94-02 randomized trial.   Proc Am Soc Ther Radiol 48:  111,2000  (abstr 2)","DOI":"10.1016\/S0360-3016(00)80019-X"},{"key":"R47-114483","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(99)00027-9"},{"key":"R48-114483","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.4.1105"},{"key":"R49-114483","doi-asserted-by":"crossref","unstructured":"Budach  VG,   Dinges  S,   Haake  K,  et al:   Accelerated chemoradiation to 70.6 Gy is more effective than accelerated radiation to 77.6 Gy alone:  Two year results of a German multicentre randomized trial.   Proc Am Soc Ther Radiol 48:  150,2000-151,    (abstr 78)","DOI":"10.1016\/S0360-3016(00)80095-4"},{"key":"R50-114483","doi-asserted-by":"crossref","unstructured":"Staar  S,   Rudat  V,   Stuetzer  H,  et al:   Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy:  Results of a multicentric randomized German trial in advanced head and neck cancer.   Proc Am Soc Ther Radiol 48:  151,2000-152,    (abstr 80)","DOI":"10.1016\/S0360-3016(00)80097-8"},{"key":"R51-114483","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.1020"},{"key":"R52-114483","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(99)00101-7"},{"key":"R53-114483","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.19.3339"},{"key":"R54-114483","unstructured":"Bonner  JA,   Ezekiel  MP,   Robert  F,  et al:   Continued response following treatment with IMC-C225, an EGFRMoAb, combined with RT in advanced head and neck malignancies.  Proc Am Soc Clin Oncol 19:  4a,2000  (abstr 5F)"},{"key":"R55-114483","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008282412670"},{"key":"R56-114483","unstructured":"Antonadou  D,   Synodinous  M,   Boufi  M,  et al:   Amifostine reduces acute toxicity during radiochemotherapy in patients with localized advanced stage NSCLC.  Proc Am Soc Clin Oncol 19:  501,2000  (abstr 1960)"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2002.11.026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:53:42Z","timestamp":1653515622000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2002.11.026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10,1]]},"references-count":54,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2002,10,1]]}},"alternative-id":["10.1200\/JCO.2002.11.026"],"URL":"https:\/\/doi.org\/10.1200\/jco.2002.11.026","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10,1]]}}}